Press coverage about Acer Therapeutics (NASDAQ:ACER) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Acer Therapeutics earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.0199660410953 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research analysts have recently commented on ACER shares. ValuEngine raised shares of Acer Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. HC Wainwright set a $50.00 price objective on shares of Acer Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 4th.
Acer Therapeutics (ACER) opened at $19.02 on Wednesday. Acer Therapeutics has a 52-week low of $5.69 and a 52-week high of $22.63. The stock has a market cap of $134.68, a PE ratio of -3.31 and a beta of 2.24.
WARNING: This article was originally published by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/opexa-therapeutics-acer-receiving-somewhat-positive-media-coverage-study-shows/1822551.html.
About Acer Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.